Correction to: Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/Formoterol 100/6 μg b.I.D.: a 12-month comparison of outcomes in mild-to-moderate asthma
After publication of the Original research article [1] it was brought to our attention that the sentence at pag 6 (between Figure 3 and Figure 4)) must be corrected as follows: “The mean duration of inactivity was 2.88 (0.63) at baseline; 1.53 (0.27) after 3; 1.40 (0.27) after 6, and 1.45 days (0.58...
Main Authors: | Roberto W. Dal Negro, Luca Bonadiman, Paola Turco |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2018-07-01
|
Series: | Multidisciplinary Respiratory Medicine |
Online Access: | http://link.springer.com/article/10.1186/s40248-018-0144-5 |
Similar Items
-
Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/Formoterol 100/6 μg b.I.D.: a 12-month comparison of outcomes in mild-to-moderate asthma
by: Roberto W. Dal Negro, et al.
Published: (2018-06-01) -
Fluticasone furoate/vilanterol 92/22 µg once a day: a 12-month study on outcomes in mild to moderate asthma
by: Roberto W. Dal Negro, et al.
Published: (2018-09-01) -
A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD
by: Bhatt SP, et al.
Published: (2017-01-01) -
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
by: Nicola C. Day, et al.
Published: (2020-06-01) -
Once-daily fluticasone furoate/vilanterol combination versus twice-daily budesonide/formoterol combination in the treatment of controlled stable asthma: a randomized crossover trial
by: Furuhashi K, et al.
Published: (2019-09-01)